Cooley M&A

OCTOBER 19, 2022

The rise of founder-led, venture capital-backed companies in recent years has coincided with a surge of companies implementing dual-class share structures in connection with their initial public offerings. Notable public deals. Amazon to Acquire One Medical for $3.9 Sixth Street Invests in Blueprint Medicines.

M&A 69

M&A Initial Public Offering Pharmaceutical Medical 69

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 23, 2024

Reverse mergers remain a fixture 2023 opened the door for reverse merger transactions to underperforming small and midsized public life sciences companies that were trading below their initial public offering price and, often, below the value of their cash on hand.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Cooley M&A

JANUARY 25, 2023

In the US, the Federal Trade Commission and the Department of Justice under the Biden administration have shifted their priorities and rhetoric in favor of tougher enforcement, with consolidation in the tech sector being one of their top targets.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Cooley M&A

JANUARY 22, 2025

This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market. The FTC nevertheless has remained focused on the life sciences/medical device sector in other parts of its enforcement efforts. Similarly, Novo Holdings $16.5

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64